Pre-Prostatectomy Lovastatin on Prostate Cancer

Stopped early · Not applicable

Conditions studied: Prostate Cancer

In brief

To determine the dose of continuous daily oral lovastatin needed to achieve MYC \[v-myc myelocytomatosis viral oncogene homolog (avian)\] down-regulation in prostatectomy specimens in intermediate-/high-risk localized prostate cancer patients.

Key facts

Study ID

NCT01478828

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

2

Starts

2012-07-13

Expected to finish

2013-04-08

Last updated by the study team

2019-03-27

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adenocarcinoma of the prostate, without evidence of spread beyond to lymph nodes, bone, or visceral organs, stage T1c or higher.
• Tumor Gleason sum of 7 (4+3 and 3+4 allowed) in at least one core, after central review of prostate biopsy at Johns Hopkins. However, in accordance with standard clinical practices, adenocarcinoma must be present in at least two discrete biopsy sections ( may vary in Gleason score).
• Age ≥18 years of age.
• Radical prostatectomy scheduled at Johns Hopkins.
• Willingness to sign and ability to understand informed consent.
• No history of treatment with any statin-class medication within 6 months of entry into the trial.
• ECOG (Eastern Cooperative Oncology Group) performance status 0-1.
• Adequate bone marrow, hepatic, and renal function as determined by:
• WBC (white blood cells) >3,500 cells/mm3 ANC (absolute neutrophil count) >1,500 cells/mm3 Hemoglobin >9 g/dl Platelet count >100,000 cells/mm3 Serum creatinine < 2.6 mg/dl Serum bilirubin <2 mg/dl ALT (alanine aminotransferase), AST (aspartate aminotransferase), and Alkaline Phosphatase <2 times the upper limit of normal Triglycerides and total cholesterol <3 times the upper limit of normal

You may not qualify if…

• Patients with evidence of metastatic prostate cancer, including bone, visceral, brain, and lymph node metastases.
• Other histologic prostate cancers, including ductal, sarcomatous, lymphoma, small cell, and neuroendocrine tumors.
• Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy including active liver disease, unexplained persistent elevation of serum transaminases, or medications that interfere with the metabolism of lovastatin, or gastrointestinal disease that would limit the ability to swallow or take oral medications or absorb them.
• Concurrent malignancy other than prostate cancer.
• Inability to provide informed consent.
• Concomitant use of azole antifungals, cyclosporine, clarithromycin, erythromycin, fibric acid derivatives, lopinavir/ritonavir, niacin, ritonavir/saquinavir
• Prior chemotherapy, radiation therapy, biologic therapy, or immunotherapy for prostate cancer.
• Poor performance status (ECOG >1).
• Prostatectomy at other hospital other than Johns Hopkins.
• Prior history of allergy or severe reaction to statins or statin derivatives.

Where it is running

• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.